Theramex And Enzene Continue Alliance With Deal For RoActemra Rival
Companies Aim To Commercialize Tocilizumab In Europe, UK, Switzerland And Australia
Theramex and Enzene have struck a deal to commercialize a tocilizumab biosimilar rival to Roche’s RoActemra in Europe – including the UK and Switzerland – as well as Australia. The two companies recently partnered for Enzene’s proposed biosimilar version of Prolia (denosumab).
